SL Science Holding Ltd SLBT
SL Science Holding Ltd (Nasdaq: SLBT) is an oncology drug developer. Its lead program, CD-19 Armed-T Therapy, is in Pre-clinical for CD19+ blood cancers (Armed-T bispecific-antibody-conjugated immune cells). Its next catalyst on record is CD-19 Armed-T Therapy: Pre-IND meeting request (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CD-19 Armed-T Therapy — Pre-IND meeting request (Q1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CD-19 Armed-T Therapy | Blood cancers | cell therapy | Pre-clinical |
| Gamma Delta T (GDT) cell therapy | Pancreatic cancer | cell therapy | Pre-clinical |
| Gamma Delta T (GDT) cell therapy | Brain cancer (glioblastoma) | cell therapy | Pre-clinical |
Recent results and decisions
- Oct 26, 2026submitted SL Science submitted an Orphan Drug Designation request to the U.S. FDA for its GDT cell therapy targeting glioblastoma.
Advanced its regulatory footprint by submitting an Orphan Drug Designation (ODD) request (DRU-2026-11528) to the U.S. FDA for its GDT cell therapy targeting glioblastoma.
Filing - Oct 26, 2026submitted The Company filed Drug Master Files (DMF) for both its GDT cells and GDT cell-derived exosomes.
The Company also filed Drug Master Files (DMF) for both its GDT cells and GDT cell-derived exosomes, establishing a standardized manufacturing foundation for future commercialization.
Filing - Oct 26, 2026positive Preclinical data demonstrated GDT cells destroy brain cancer and chemotherapy-resistant glioblastoma cells.
In July 2026, SL Science exhibited data at the World Congress of Basic and Clinical Pharmacology showing potent destruction of brain cancer cells in preclinical models.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
- Legend Biotech Corp LEGN
- Veracyte, Inc. VCYT
- Indaptus Therapeutics, Inc. INDP
- YD Bio Ltd YDES
- OnKure Therapeutics, Inc. OKUR
- Boundless Bio, Inc. BOLD
- NextCure, Inc. NXTC
- Akari Therapeutics Plc AKTX
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.